CLINICAL TRIALS PROFILE FOR RECARBRIO
✉ Email this page to a colleague
All Clinical Trials for RECARBRIO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04493151 ↗ | Imipenem/Cilastatin/Relebactam PK in ECMO | Recruiting | Merck Sharp & Dohme Corp. | Phase 1 | 2021-01-01 | Extracorporeal membrane oxygenation (ECMO) is a from of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and re-infused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, imipenem-cilastatin-relebactam, in critically ill patients receiving ECMO. |
| NCT04493151 ↗ | Imipenem/Cilastatin/Relebactam PK in ECMO | Recruiting | Joseph L. Kuti, PharmD | Phase 1 | 2021-01-01 | Extracorporeal membrane oxygenation (ECMO) is a from of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and re-infused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, imipenem-cilastatin-relebactam, in critically ill patients receiving ECMO. |
| NCT04785924 ↗ | Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections | Recruiting | Merck Sharp & Dohme Corp. | Phase 4 | 2021-06-07 | This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam (IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam CZA) in treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae infections at a tertiary care hospital. The objectives of the study are to demonstrate successful treatment of KPC containing Enterobacteriaceae infections with IMI/REL including in bacteremia, and to analyze treatment outcomes in use of IMI/REL for KPC-producing infections compared to historical clinical outcome data with CZA and MVB use at the same institution. |
| NCT04785924 ↗ | Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections | Recruiting | Atrium Health | Phase 4 | 2021-06-07 | This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam (IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam CZA) in treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae infections at a tertiary care hospital. The objectives of the study are to demonstrate successful treatment of KPC containing Enterobacteriaceae infections with IMI/REL including in bacteremia, and to analyze treatment outcomes in use of IMI/REL for KPC-producing infections compared to historical clinical outcome data with CZA and MVB use at the same institution. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RECARBRIO
Condition Name
Clinical Trial Locations for RECARBRIO
Trials by Country
Clinical Trial Progress for RECARBRIO
Clinical Trial Phase
Clinical Trial Sponsors for RECARBRIO
Sponsor Name
